Communicators

 Planegg/Martinsried (19.10.2020) - Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the treatment of cancer, has concluded a service agreement with Cytovant Sciences HK Limited, a biopharmaceutical company founded by Roivant Sciences (Roivant/Cytovant), to support process development activities for the manufacturing of dendritic cell (DC) vaccines. The service agreement builds on Medigene's license and cooperation agreements with Roivant/Cytovant which cover three TCR projects and Medigene's DC vaccine program targeting ... [ more ]